(Q51561686)

7 April 2018

title

Improved fibrinolysis by intense lifestyle intervention. A randomized trial in subjects with impaired glucose tolerance. (English)

1 reference

7 April 2018

main subject

randomized experiment

1 reference

5

Hallmans G

1 reference

7 April 2018

Lindahl B

1

1 reference

7 April 2018

Nilsson TK

series ordinal

2

1 reference

7 April 2018

Jansson JH

series ordinal

3

1 reference

7 April 2018

Asplund K

series ordinal

4

1 reference

7 April 2018

language of work or name

English

0 references

publication date

1 July 1999

1 reference

7 April 2018

Journal of Internal Medicine

published in

1 reference

7 April 2018

volume

246

1 reference

7 April 2018

issue

1

1 reference

7 April 2018

page(s)

105-112

1 reference

7 April 2018

Banting lecture 1988. Role of insulin resistance in human disease

uses

randomized experiment

0 references

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.1999.00537.X

Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.1999.00537.X

Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.1999.00537.X

Insulin resistance syndrome and fibrinolytic activity: the northern Sweden MONICA study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.1999.00537.X

Hyperinsulinemia. A link between hypertension obesity and glucose intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.1999.00537.X

Pathogenesis of NIDDM. A balanced overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.1999.00537.X

Evidence for a rapid inhibitor to tissue plasminogen activator in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.1999.00537.X

Insulin, health behaviors, and lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.1999.00537.X

Quantification of exercise capability and evaluation of physical capacity in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.1999.00537.X

Endogenous tissue-type plasminogen activator and risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.1999.00537.X

Normal plasminogen activator inhibitor levels at long-term follow-up after jejuno-ileal bypass surgery in morbidly obese individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.1999.00537.X

Intense nonpharmacological intervention in subjects with multiple cardiovascular risk factors: decreased fasting insulin levels but only a minor effect on plasma plasminogen activator inhibitor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.1999.00537.X

Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.1999.00537.X

10.1046/J.1365-2796.1999.00537.X

21 January 2018

Identifiers

DOI

1 reference

7 April 2018

1 reference

7 April 2018